Scholar Rock Holding Corporation (SRRK) is a leading biopharmaceutical company that specializes in discove ring, designing, and developing new treatments targeting the transforming growth factor beta (TGFβ) superfamily of proteins. The company was founded in 2012 and has its headquarters in Cambridge, Massachusetts. It is well-known for its unique and proprietary platform that allows the specific targeting of latent TGFβ, a key component of numerous biological processes.
Scholar Rock’s platform is engineered to exploit the complexity of the TGFβ biology by specifically targeting and modulating its activation in a controlled way. This includes designing therapeutic antibodies that can precisely target these powerful proteins, which play key roles in a variety of conditions, including oncology, fibrosis, and immunology, among others.
An innovative forerunner in the field of biopharmaceuticals, Scholar Rock’s most advanced product candidate is SRK-015, an antibody against myostatin, which is in clinical development for the treatment of Spinal Muscular Atrophy (SMA). The company is committed to addressing unmet medical needs by delivering safer and more effective therapies to patients worldwide.
Scientific breakthroughs are at the core of Scholar Rock’s strategy. The company’s unique approach to understanding and targeting TGFβ activation empowers it to create innovative therapeutics that could revolutionize treatments for a broad range of serious diseases. One example is cancer, where TGFβ has been implicated both as a potential tumour promoter and suppressor, offering multiple avenues for new drug pipelines.
Scholar Rock has assembled a world-class team of researchers, clinical development experts, and industry leaders, creating a collaborative environment that nurtures scientific excellence and innovation. By combining a deep understanding of molecular biology with cutting-edge technology, the company is continually pushing the boundaries of what’s possible in drug discovery and development.
Since its inception, Scholar Rock has established numerous collaborations and partnerships with leading pharmaceutical and biotech companies. This indicates the wider industry’s recognition of the potential and value of Scholar Rock’s technology and therapeutic candidates. As its portfolio of therapeutic candidates grows, Scholar Rock continues to impact the lives of patients on a global scale.
Scholar Rock Holding Corp is listed on the NASDAQ Global Market under the ticker symbol "SRRK". Despite the typical challenges and risks tied to drug development, Scholar Rock remains steadfast in its mission of pioneering new frontiers in biomedical science, while keeping patient needs at the forefront of its endeavor.